TrialClinical cancer research : an official journal of the American Association for Cancer Research2018

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

Maura N Dickler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.